These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 30609388)
41. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. Ito Y; Kikuchi E; Tanaka N; Kosaka T; Suzuki E; Mizuno R; Shinojima T; Miyajima A; Umezawa K; Oya M BMC Cancer; 2015 Apr; 15():324. PubMed ID: 25926105 [TBL] [Abstract][Full Text] [Related]
42. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses. de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706 [TBL] [Abstract][Full Text] [Related]
43. Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. Tian F; Zhang C; Tian W; Jiang Y; Zhang X Oncol Rep; 2012 Jul; 28(1):232-40. PubMed ID: 22552693 [TBL] [Abstract][Full Text] [Related]
44. Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models. Meng XB; Bi XL; Zhao HL; Feng JB; Zhang JP; Song GM; Sun WY; Bi YW Transplant Proc; 2013; 45(6):2553-8. PubMed ID: 23953580 [TBL] [Abstract][Full Text] [Related]
45. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Xu Y; Poggio M; Jin HY; Shi Z; Forester CM; Wang Y; Stumpf CR; Xue L; Devericks E; So L; Nguyen HG; Griselin A; Gordan JD; Umetsu SE; Reich SH; Worland ST; Asthana S; Barna M; Webster KR; Cunningham JT; Ruggero D Nat Med; 2019 Feb; 25(2):301-311. PubMed ID: 30643286 [TBL] [Abstract][Full Text] [Related]
46. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236 [TBL] [Abstract][Full Text] [Related]
47. Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. Jeong H; Kim S; Hong BJ; Lee CJ; Kim YE; Bok S; Oh JM; Gwak SH; Yoo MY; Lee MS; Chung SJ; Defrêne J; Tessier P; Pelletier M; Jeon H; Roh TY; Kim B; Kim KH; Ju JH; Kim S; Lee YJ; Kim DW; Kim IH; Kim HJ; Park JW; Lee YS; Lee JS; Cheon GJ; Weissman IL; Chung DH; Jeon YK; Ahn GO Cancer Res; 2019 Feb; 79(4):795-806. PubMed ID: 30610087 [TBL] [Abstract][Full Text] [Related]
49. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Lin C; He H; Liu H; Li R; Chen Y; Qi Y; Jiang Q; Chen L; Zhang P; Zhang H; Li H; Zhang W; Sun Y; Xu J Gut; 2019 Oct; 68(10):1764-1773. PubMed ID: 30661053 [TBL] [Abstract][Full Text] [Related]
50. Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion. Xia X; Zhou W; Guo C; Fu Z; Zhu L; Li P; Xu Y; Zheng L; Zhang H; Shan C; Gao Y Front Oncol; 2018; 8():632. PubMed ID: 30619766 [TBL] [Abstract][Full Text] [Related]
51. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway. Cai H; Yan L; Liu N; Xu M; Cai H Biomed Pharmacother; 2020 Mar; 123():109790. PubMed ID: 31896065 [TBL] [Abstract][Full Text] [Related]
52. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941 [TBL] [Abstract][Full Text] [Related]
53. Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression. Wang W; Chapman NM; Zhang B; Li M; Fan M; Laribee RN; Zaidi MR; Pfeffer LM; Chi H; Wu ZH Cancer Res; 2019 Jun; 79(11):2909-2922. PubMed ID: 30737234 [TBL] [Abstract][Full Text] [Related]
54. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Ebrahimi N; Abdulwahid ARR; Mansouri A; Karimi N; Bostani RJ; Beiranvand S; Adelian S; Khorram R; Vafadar R; Hamblin MR; Aref AR Cell Mol Life Sci; 2024 Feb; 81(1):106. PubMed ID: 38418707 [TBL] [Abstract][Full Text] [Related]
55. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Bai X; Guo ZQ; Zhang YP; Fan ZZ; Liu LJ; Liu L; Long LL; Ma SC; Wang J; Fang Y; Tang XR; Zeng YJ; Pan X; Wu DH; Dong ZY Nat Commun; 2023 Mar; 14(1):1247. PubMed ID: 36871040 [TBL] [Abstract][Full Text] [Related]
56. The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer. Wang Y; Yuan X; Li J; Liu Z; Li X; Wang Z; Wei L; Li Y; Wang X Front Cell Dev Biol; 2021; 9():785796. PubMed ID: 34977029 [TBL] [Abstract][Full Text] [Related]
57. NF-κB and Its Role in Checkpoint Control. Betzler AC; Theodoraki MN; Schuler PJ; Döscher J; Laban S; Hoffmann TK; Brunner C Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486375 [TBL] [Abstract][Full Text] [Related]
58. CDK4 Inhibitors Thwart Immunity by Inhibiting Phospho-RB-NF-κB Complexes. Kim SJ; Asfaha S; Dick FA Mol Cell; 2019 Jan; 73(1):1-2. PubMed ID: 30609388 [TBL] [Abstract][Full Text] [Related]
59. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Jin X; Ding D; Yan Y; Li H; Wang B; Ma L; Ye Z; Ma T; Wu Q; Rodrigues DN; Kohli M; Jimenez R; Wang L; Goodrich DW; de Bono J; Dong H; Wu H; Zhu R; Huang H Mol Cell; 2019 Jan; 73(1):22-35.e6. PubMed ID: 30527665 [TBL] [Abstract][Full Text] [Related]